Product information and disease descriptionPlace of product in therapyDisease description
Pathophysiology
6 evidence topics · 7 sources
Constitutive activation of the Wnt/β-catenin pathway
“Approximately 85–90% of sporadic cases of DT show activating mutations in the N-terminal region of CTNNB1 (all of them in exon 3)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“making β-catenin more resistant to proteolytic degradation, leading to cytoplasmic accumulation of the protein and its subsequent translocation to the nucleus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In ~5–10% of patients, DT results from germline (i.e., in FAP) or sporadic loss-of-function mutations in the APC tumor suppressor gene.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although the molecular pathogenesis of desmoid tumors is not fully understood, dysregulation of the Wnt/β-catenin pathway and consequent transcription of prosurvival and proliferative genes likely play a critical role.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mutual exclusivity of CTNNB1 and APC mutations
Notch pathway cross-talk and overexpression
“Cross-talk between the Notch and Wnt pathways, as well as activation of the Notch pathway resulting from dysregulation of the Wnt pathway, suggest a possible therapeutic target for DT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subsequent studies analyzed the expression of Notch pathway components in DT tissues and cell strains, and confirmed increased expression of HES1 in DT versus dermal scar tissue” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dysregulation of the Wnt signaling pathway plays a key role in DT pathogenesis, however, as the result of crosstalk, Wnt dysregulation may lead to activation of the Notch pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overexpression of Notch pathway components in DT provides a rationale for development of pharmacologic agents targeting Notch.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to the role γ-secretase plays in Notch signaling through cleavage of the Notch intracellular domain (with subsequent translocation to the nucleus to activate gene transcription), γ-secretase inhibitors (GSIs) have emerged as a potential treatment for DT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CTNNB1 genotype and tumor behavior
“Five-year recurrence-free survival was significantly poorer in 45F-mutated desmoids (23%, P < 0.0001) versus either 41A (57%) or nonmutated tumors (65%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“DF harboring p.S45F was significantly associated with male sex (P = 0.03), non-abdominal wall sites (P = 0.05), pain (P = 0.007), and large tumor size (P = 0.025). CTNNB1 p.S45F mutation was not significantly associated with EFS, either in univariate (HR, 1.06; 95% CI, 0.65-1.73; P = 0.81) or in multivariate analysis (HR, 0.91; 95% CI, 0.55-1.49; P = 0.71).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote